|
Synonyms: HuMax-TF-ADC | TF-011-MMAE | tisotumab vedotin-tftv | Tivdak®
tisotumab vedotin is an approved drug (FDA (2021))
Compound class:
Antibody
Comment: Tisotumab vedotin is an antibody-drug conjugate (ADC) of an anti-factor 3 monoclonal antibody that is conjugated to the antineoplastic agent monomethyl auristatin E (MMAE; PubChem CID 11542188) [1]. Tisotumab vedotin causes adverse events that are associated with disrupted coagulation [4].
|
Classification  |
|
| Compound class | Antibody |
| Approved drug? | Yes (FDA (2021)) |
| Approved drug? | Yes. FDA (2021) |
| International Nonproprietary Names |
|
| INN number | INN |
| 10148 | tisotumab vedotin |
| Synonyms |
| HuMax-TF-ADC | TF-011-MMAE | tisotumab vedotin-tftv | Tivdak® |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 571 |
| Other databases | |
| GtoPdb PubChem SID | 458923754 |
| Search PubMed clinical trials | tisotumab vedotin |
| Search PubMed titles | tisotumab vedotin |
| Search PubMed titles/abstracts | tisotumab vedotin |
